Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhe Sheng

Showing results (1-10 of 667) with videos related to

Pageof 67
Sort By:
Current Pharmaceutical Biotechnology|April 22, 2011
ABC transporters in pharmacology/physiology and human diseasesZhe-Sheng Jason Chen
Science (New York, N.Y.)|June 26, 2025
A caged drug enables precision deliveryYuhao Xie, Zhe-Sheng Chen
Signal Transduction and Targeted Therapy|March 18, 2022
Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failureLiwu Fu, Zhe-Sheng Chen
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 29, 2026
Adaptive lineage plasticity drives multidrug resistance to KRAS-EGFR targeted therapyJianyou Gu, Zhe-Sheng Chen
Cancers|December 4, 2015
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation TherapyAnna Maria Barbuti, Zhe-Sheng Chen
Bosnian Journal of Basic Medical Sciences|August 25, 2021
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signatureZhe-Sheng Chen, Dong-Hua Yang
Recent Patents on Anti-Cancer Drug Discovery|November 13, 2025
PrefaceZhe-Sheng Jason Chen, Bohan Zhang
The FEBS Journal|July 12, 2011
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseasesZhe-Sheng Chen, Amit K Tiwari
AI Zheng = Aizheng = Chinese Journal of Cancer|December 17, 2004
[Establishment of tumor cell membrane model and screening for specific anti-tumor peptides]Zhe-Sheng Wen, Tie-Hua Rong
Frontiers in Pharmacology|June 28, 2013
Repurposing phosphodiesterase-5 inhibitors as chemoadjuvantsAmit K Tiwari, Zhe-Sheng Chen
Pageof 67

Showing results (1-10 of 667) with videos related to

Sort By:
Pageof 67
Current Pharmaceutical Biotechnology|April 22, 2011
ABC transporters in pharmacology/physiology and human diseasesZhe-Sheng Jason Chen
Science (New York, N.Y.)|June 26, 2025
A caged drug enables precision deliveryYuhao Xie, Zhe-Sheng Chen
Signal Transduction and Targeted Therapy|March 18, 2022
Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failureLiwu Fu, Zhe-Sheng Chen
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 29, 2026
Adaptive lineage plasticity drives multidrug resistance to KRAS-EGFR targeted therapyJianyou Gu, Zhe-Sheng Chen
Cancers|December 4, 2015
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation TherapyAnna Maria Barbuti, Zhe-Sheng Chen
Bosnian Journal of Basic Medical Sciences|August 25, 2021
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signatureZhe-Sheng Chen, Dong-Hua Yang
Recent Patents on Anti-Cancer Drug Discovery|November 13, 2025
PrefaceZhe-Sheng Jason Chen, Bohan Zhang
The FEBS Journal|July 12, 2011
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseasesZhe-Sheng Chen, Amit K Tiwari
AI Zheng = Aizheng = Chinese Journal of Cancer|December 17, 2004
[Establishment of tumor cell membrane model and screening for specific anti-tumor peptides]Zhe-Sheng Wen, Tie-Hua Rong
Frontiers in Pharmacology|June 28, 2013
Repurposing phosphodiesterase-5 inhibitors as chemoadjuvantsAmit K Tiwari, Zhe-Sheng Chen
Pageof 67